Cellectar Biosciences, Inc. disclosed that it had approximately $25.9 million of cash and cash equivalents as of June 30, 2024, and announced positive results from its ongoing CLOVER WaM pivotal study for the treatment of relapsed/refractory Waldenstrom's macroglobulinemia patients.